rel
littl
known
preval
morbid
mortal
copd
develop
countri
includ
region
recent
studi
thailand
estim
preval
copd
per
peopl
risk
smoker
age
year
estim
base
number
peopl
hospit
copd
therefor
repres
preval
moder
sever
diseas
whoworld
bank
studi
estim
preval
copd
differ
area
world
use
inform
expert
opinion
extrapol
compar
region
publish
data
lack
suggest
preval
copd
china
male
femal
estim
challeng
recent
report
overal
copd
preval
per
peopl
age
year
three
region
china
whoworld
bank
studi
also
estim
copd
preval
male
femal
asia
island
amalgam
countri
island
state
region
furthermor
data
studi
use
extrapol
copd
preval
figur
per
peopl
entir
asian
popul
estim
necessarili
base
actual
epidemiolog
data
provid
reliabl
inform
precis
preval
copd
region
turn
mean
govern
unawar
region
econom
human
impact
copd
therefor
unabl
plan
effect
strategi
reduc
burden
diseas
epidemiolog
studi
logist
difficult
expens
conduct
altern
method
assess
copd
preval
make
use
computer
tool
predict
preval
basi
local
copd
risk
factor
data
preval
smoke
exposur
biomass
fuel
air
pollut
occup
etc
shown
overal
preval
clinic
signific
copd
amongst
adult
year
old
region
approxim
data
suggest
copd
signific
problem
region
previous
realis
furthermor
trend
risk
factor
increas
incid
smoke
greater
longev
associ
increas
risk
succumb
chronic
diseas
copd
increas
exposur
environment
pollut
suggest
preval
copd
region
like
increas
come
year
intern
group
copd
expert
met
discuss
develop
global
initi
chronic
obstruct
lung
diseas
gold
us
nation
institut
health
heart
lung
blood
institut
nhlbi
gold
expert
panel
consist
health
profession
around
world
expertis
respiratori
medicin
epidemiolog
socioeconom
public
health
health
educ
model
initi
global
initi
asthma
gina
intern
strategi
develop
comprehens
guidelin
asthma
control
manag
use
committe
expert
gold
expert
panel
agre
object
gold
increas
awar
copd
amongst
govern
public
health
offici
healthcar
worker
gener
public
improv
prevent
manag
diseas
decreas
copd
morbid
mortal
encourag
new
research
diseas
gold
expert
panel
conduct
workshop
review
exist
copd
guidelin
advanc
understand
diseas
ultim
aim
prepar
consensu
guidelin
documentglob
strategi
diagnosi
manag
prevent
copd
publish
full
workshop
report
execut
summari
form
earli
updat
gold
guidelin
base
clinic
research
publish
june
march
impact
manag
copd
publish
juli
report
present
guidelin
copd
diagnosi
manag
importantli
includ
grade
b
c
weight
scientif
evid
support
recommend
gold
strategi
present
copd
manag
plan
divid
four
compon
assess
monitor
diseas
ii
reduct
risk
factor
iii
manag
stabl
copd
iv
manag
exacerb
inform
recommend
present
gold
report
base
current
concept
copd
pathogenesi
avail
evid
appropri
manag
prevent
strategi
content
report
develop
expert
copd
research
clinic
manag
extens
review
expert
scientif
societi
nhlbi
public
gold
guidelin
audit
implement
assess
impact
programm
outcom
updat
gold
guidelin
includ
follow
chang
classif
system
modifi
mild
ii
moder
iii
sever
iv
sever
ii
moder
sever
copd
use
regular
treatment
bronchodil
includ
tiotropium
rather
bronchodil
recommend
evid
level
iii
inhal
glucocorticosteroid
recommend
patient
copd
sever
iii
frequent
exacerb
evid
level
iv
rehabilit
programm
month
durat
evid
level
b
v
home
care
repres
effect
practic
altern
hospit
select
patient
exacerb
copd
without
acidot
respiratori
failur
gold
recommend
intend
univers
applic
expert
panel
drew
attent
possibl
difficulti
implement
gold
recommend
develop
countri
thu
gold
expert
panel
note
reproduc
inexpens
methodolog
suitabl
use
develop
countri
need
evalu
use
encourag
spiromet
need
develop
ensur
econom
accur
perform
rel
untrain
oper
administ
test
method
strategi
implement
copd
manag
program
develop
countri
requir
special
attent
thu
gold
expert
panel
acknowledg
aspect
gold
guidelin
may
requir
amend
ensur
relev
applic
use
develop
countri
region
task
taken
copd
roundtabl
group
copd
roundtabl
group
taskforc
expert
respirologist
region
met
time
per
year
sinc
juli
copd
roundtabl
group
support
societi
respirolog
apsr
support
educ
grant
boehring
ingelheim
pfizer
main
object
copd
roundtabl
group
increas
awar
copd
region
ii
assess
region
relev
applic
gold
guidelin
facilit
implement
iii
identifi
problem
specif
region
discuss
resolut
iv
stimul
region
collabor
research
copd
note
howev
one
main
reason
establish
copd
roundtabl
group
facilit
region
implement
gold
guidelin
end
roundtabl
group
develop
consensu
statement
implement
gold
strategi
copd
region
access
spirometri
diagnosi
copd
could
suspect
basi
histori
symptom
physic
sign
spirometri
avail
peak
flow
measur
use
exclud
asthma
diagnos
forc
expiratori
time
fet
time
taken
individu
forc
exhal
open
mouth
total
lung
capac
airflow
becom
inaud
time
taken
exhal
record
stopwatch
abnorm
prolong
good
guid
presenc
ratio
ie
obstruct
diseas
chest
recommend
diagnos
copd
use
exclud
common
diseas
give
rise
airway
obstruct
eg
tuberculosi
bronchiectasi
lung
cancer
etc
littl
correl
peak
flow
measur
symptom
longitudin
studi
copd
patient
copd
patient
improv
symptom
qualiti
life
without
improv
lung
function
group
recommend
use
serial
measur
peak
flow
assess
monitor
respons
mrc
dyspnoea
scale
use
diagnosi
copd
function
scale
use
assess
short
breath
disabl
assist
evalu
diseas
sever
wherev
possibl
copd
patient
receiv
bronchodil
therapi
via
inhal
rout
howev
oral
bronchodil
theophyllin
may
appropri
cost
inhal
bronchodil
barrier
treatment
patient
difficulti
master
inhal
techniqu
mdi
tri
use
spacer
mdi
differ
type
spacer
inhal
devic
experi
attempt
identifi
devic
patient
use
easili
effect
inhal
techniqu
patient
requir
train
use
spacer
effect
approach
conveni
recommend
treatment
nebul
nebul
may
avail
mani
copd
patient
region
expens
requir
power
sourc
fill
nebul
solut
furthermor
area
affect
sever
acut
respiratori
syndrom
sar
thought
risk
transmiss
viru
may
reduc
use
spacer
devic
use
mdi
spacer
place
nebul
recommend
treatment
acut
airflow
obstruct
patient
copd
attempt
reduc
risk
droplet
transmiss
respiratori
infect
sar
consid
differenti
diagnosi
acut
exacerb
copd
sar
suspect
patient
triag
recommend
bronchodil
treatment
delay
deni
patient
treat
patient
experienc
acut
exacerb
import
ensur
bronchodil
dosag
adequ
titrat
frequent
interv
base
patient
respons
use
spacer
instead
nebul
recommend
appropri
ventilatori
support
delay
deni
patient
burden
suspect
sar
reduc
influenza
vaccin
copd
patient
influenza
vaccin
highli
recommend
copd
patient
within
region
could
recurr
sar
mimic
clinic
present
influenza
patient
vaccin
month
prior
anticip
peak
incid
influenza
copd
roundtabl
group
recommend
vaccin
patient
copd
commun
high
likelihood
sar
remain
issu
regard
implement
influenza
vaccin
copd
patient
region
follow
reason
low
surveil
data
tropic
countri
ii
appar
lack
bimod
season
tropic
countri
iii
uncertainti
appropri
frequenc
time
vaccin
iv
presenc
two
potenti
vaccin
formul
coincid
influenza
strain
emerg
februari
septemb
v
limit
efficaci
data
vaccin
tropic
countri
vi
lack
studi
countri
bimod
peak
rel
lack
season
influenza
infect
choic
vaccin
left
physician
although
limit
evid
within
region
simplifi
pulmonari
rehabilit
program
includ
crucial
element
regular
exercis
train
patient
educ
found
workabl
recommend
train
program
involv
simpl
structur
element
baselin
walk
test
determin
workload
requir
follow
regular
session
walk
min
ideal
upper
limb
exercis
pivot
success
pulmonari
rehabilit
educ
initi
may
undertaken
train
physiotherapist
improv
patient
awar
import
smoke
cessat
manag
copd
initi
aid
enhanc
patient
improv
rapport
patient
physiotherapist
uncondit
educ
grant
boehring
ingelheim
pfizer
cover
cost
group
meet
write
consensu
statement
deliber
group
free
influenc
fund
compani
member
asia
pacif
copd
roundtabl
group
act
consult
sever
pharmaceut
compani
includ
boehring
ingelheim
pfizer
spoken
meet
sponsor
pharmaceut
compani
includ
boehring
ingelheim
pfizer
